Italia markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,30-0,01 (-0,19%)
Al 02:17PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente5,31
Aperto5,31
Denaro5,31 x 900
Lettera5,33 x 800
Min-Max giorno5,12 - 5,39
Intervallo di 52 settimane4,38 - 14,04
Volume540.162
Media Volume805.787
Capitalizzazione323,681M
Beta (5 anni mensile)-1,01
Rapporto PE (ttm)N/D
EPS (ttm)-1,14
Prossima data utili07 nov 2023 - 13 nov 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A16,63
  • GlobeNewswire

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that it has granted as of September 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement A

  • GlobeNewswire

    Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

    FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September. 2023 Wells Fargo Healthcare Conference

  • GlobeNewswire

    Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

    - Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 (THR-β) in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 (allosteric BCR-ABL) Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 (GLP-1) program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to ini